ETH47: The Asthma Drug That Could Redefine Respiratory Care

ETH47: The Asthma Drug That Could Redefine Respiratory Care

By, Admin 7 August 2025

A new era in asthma treatment may be unfolding. Ethris GmbH, a clinical-stage biotech company, has just dosed the first patient in a pivotal Phase 2a clinical trial for ETH47, its lead mRNA-based antiviral therapy.

What Makes ETH47 Different?

ETH47 isn’t just another asthma medication. It’s a first-in-class candidate with a novel mechanism:

  • Encodes Interferon Lambda (IFN-λ): A protein that boosts viral immunity in the airways.
  • Administered intranasally: Targets respiratory infections directly at the entry point.
  • No systemic exposure: Minimizes risk of off-target effects and unwanted side effects.

Unlike traditional asthma drugs that only reduce inflammation or suppress symptoms, ETH47 aims to stop asthma attacks before they begin, by attacking the viral triggers.

Key Trial Details: What’s Happening Now?

Ethris is conducting the study (ISRCTN21576805) in London, UK, with VirTus Respiratory Research Ltd. It’s randomized, double-blind, and placebo-controlled.

Here’s what the trial looks like:

  • Participants: 50 adults with asthma.
  • Challenge: Each is exposed to rhinovirus, a known asthma trigger.
  • Treatment: Half receive ETH47, half receive placebo.
  • Primary Endpoint: Improvement in Lower Respiratory Symptoms Score (LRSS), tracked twice daily.

ETH47 has already cleared Phase 1 with positive safety, tolerability, and local activity in the respiratory tract.

Expert Opinions: Why This Could Be a Breakthrough

“ETH47 may fundamentally change how asthma is managed,”

  • Dr. Thomas Langenickel, Chief Medical Officer, Ethris

“This directly addresses the viral root of asthma exacerbations,”

  • Professor Sebastian Johnston, Imperial College London

These are not just optimistic projections. The drug’s mutation-independent action may offer broad protection against current and future respiratory viruses.

What Comes Next?

If Phase 2a results are positive, Ethris plans to:

  • Launch a broader Phase 2b trial
  • Explore ETH47’s role in reducing asthma exacerbations
  • Potentially shift how chronic respiratory diseases are managed

The Science Behind ETH47

ETH47 is powered by two key platforms:

  • SNIM RNA: A stabilized, non-immunogenic mRNA platform
  • SNaP LNP: A proprietary lipidoid nanoparticle delivery system

Together, they allow localized, potent activation of the body’s innate immune response without widespread side effects.

Final Thoughts

ETH47 may be the first of many mRNA-based treatments to proactively manage respiratory diseases.

Instead of reacting to asthma attacks, we could soon prevent them.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!